Interview with Carlos Kiffer, President, GC-2
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
Address: Av. Nações Unidas, 12.399, 12º andar, cj 125 A, Edifício Landmark CEP 04578-000, São Paulo – SP,Brazil
Tel: (11) 3528 7406
Web: http://www.gcdois.com.br/
GC-2, in tune with the surge in R&D for pharmaceutical products in the region, provides intelligent solutions for this interdisciplinary scenario.
The natural growth of pharmaceuticals in the region, including herbal medicines and biotechnology products, has caused a parallel demand for project management. However, GC-2 is not just one more consulting firm. We bring the Project Management Office concept to pharmaceutical R&D.
In order to strengthen the strategic decision making process in pharmaceutical drug and product development, GC-2 offers its clients alternatives for the technical and commercial scientific monitoring of their developments:
Technical and scientific viability and patentability, Conceptualization & positioning, Structuring & management, Production and quality insurance interface, Pre-clinical pharmacological development interface, Pre-clinical toxicological development interface, Clinical development, Public agency interface, Antimicrobial development
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
Novo Nordisk’s Latin America lead Allan Finkel outlines the “alarming” burden of diabetes and obesity in his region, the progress that has been made via national campaigns against diabetes, and…
GSK’s head of Emerging Markets, Luis Arosemena, comments on the strategic importance of this wide-ranging country grouping for the company, the structure of his organisation in Latin America, the importance…
The latest from Brazilian Pharma, including the approval of home grown cannabis for medical use, Cellera Farma’s partnership with Ferring, a considerable increase in demand for oncology drugs, and a…
The latest from the healthcare industry in Latin America, including an alarming OECD report about the decline of well-being in the region due to Covid-19, Bayer’s USD 350 million investment…
The latest news from Brazil, including Pfizer’s plans to vaccinate the entire Brazilian city of Toledo, what the US can learn from Brazil’s successful vaccine campaign, and a new deal…
The latest news from Brazilian pharma, including an investigation into the country’s deal with Indian lab Bharat Biotech to purchase COVID-19 vaccines; the IP and regulatory challenges around personalised medicine…
Founded in 1950, EMS is one of the top two domestic pharma companies in Brazil. As a key player in the largest and most populous nation in Latin America, the…
The Brazilian pharma market outperformed the Latin American average in Q1 of 2020 with a growth of 8.2 percent in real terms (inflation adjusted), according to IQVIA. Its size reached…
Six of the top ten companies in the Brazilian pharma market are domestic.* Read on for an introduction to some of the Brazilian giants that are perhaps less well known…
Panorama Faramceutico’s editorial team look at how the ongoing COVID-19 pandemic stands to affect Brazil’s over the counter (OTC) market segment during and after the COVID-19 pandemic.* The OTC…
In the race to develop the world’s first COVID-19 vaccine, Brazil – now one of the world’s worst-affected countries – is becoming an attractive clinical trial destination for biopharma companies…
The editorial team at Panorama Farmaceutico explain how the COVID-19 pandemic and global trade flow stoppages are impacting the manufacture and supply of medicines within Brazil.* The COVID-19 pandemic…
See our Cookie Privacy Policy Here
